

A Study of Spontaneous Bacterial Peritonitis in Cirrhosis of Liver with Ascites with Special Reference to Serial Ascitic Fluid Cell Count as Prognostic Marker

Dr. Sushanth Vemuganti¹; Dr.M. K.Sagar²; Dr.S.C.Mohapatra³;
Dr. P. Satya Raju⁴; Dr. S. Prasanna Kumar⁵, Dr. K. S. Roshni⁶.

¹Dr. Sushanth Vemuganti, Junior Resident, General Medicine, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram Dist, AP, India.

²Dr.M. K. Sagar, M.D., General Medicine, Professor, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram Dist, AP, India.

³Dr.S.C.Mohapatra M.D., General Medicine, Professor & HOD, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram Dist, AP, India.

⁴Dr.P. Satya Raju, General Medicine, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram Dist, AP, India.

⁵Dr. S. Prasanna Kumar, Junior Resident, General Medicine, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram Dist, AP, India.

⁶Dr. K. S. Roshni, Junior Resident, General Medicine, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram Dist, AP, India.

Correspondence Author: Dr. Sushanth Vemuganti

Abstract:

Aim: To study clinical features and prognostic significance of various clinical, biochemical parameters and serial ascitic fluid cell count in SBP.

Study design: Prospective, observational, single centre, non-blind (open label).

Place and duration of study: General Medicine Department, Maharaja's Institute of Medical Sciences, Nellimarla, Vizianagaram, Vizianagaram Dist, India from October 2014 to September 2016.

Methodology: 50 patients admitted to MIMS General Hospital, Nellimarla, diagnosed as cirrhosis of liver with SBP were studied. SBP was diagnosed based on ascitic fluid cell PMN count of > 250. Serial ascitic fluid cell count was done at 0 hour, 24 hours, 48 hours, and at 5 days. The results were compared between the survivors and non-survivors and subjected to appropriate statistical analysis.

Results: Male:Female ratio in SBP patients was 2:1. Mean age at the time of diagnosis was 53.68 +/- 9.06 years (37 – 75 years). Common clinical features were - jaundice(64 %), fever(56 %), abdomen pain(56 %), altered sensorium(40%), haemetemesis or malena (36 %) and oliguria(32 %), icterus (84 %), asterixis (48 %), hypotension (24 %), abdominal tenderness (68%). Ascitic fluid culture did not show any growth in 48 % of cases while 24 % showed E. Coli, 20 % showed klebsiella, and 4 % each of proteus and staphylococcus aureus. Outcome was grave with 44 % mortality.

Conclusion: : TLC above 11,000/mm³, total bilirubin above > 5mg/dl and sr. creatinine > 1.5 were associated with increased mortality. An ascetic fluid PMN count of > 600 at time of diagnosis, > 700 at 24 hours and > 450 at 48hours was associated with poor prognosis. A progressive fall in serial ascitic fluid cell PMN count was associated with good prognosis.

Key Words: SBP and serial ascitic fluid cell count.

Date of Submission: 03-01-2018

Date of acceptance: 22-01-2018

I. Introduction

Cirrhosis of liver is the common hepatic disorder seen in day to day clinical practice. The mortality in cirrhosis patients mainly because of the complications like hepatic encephalopathy and spontaneous bacterial peritonitis. One of the factors which are responsible for subsequent deterioration in the condition of cirrhosis patient is appearance of spontaneous bacterial peritonitis (SBP). Spontaneous bacterial peritonitis is most common life-threatening, infectious complication in patients with ascites characterized by abrupt onset of fever, chills, abdominal pain with rebound tenderness over abdomen, absent bowel sounds and leucocytosis. Paracentesis reveals cloudy ascitic fluid with many WBCs predominantly, polymorphonuclear cells (PMN). SBP is defined as the infection of previously sterile ascitic fluid without an apparent intra-abdominal source of

infection. A single organism usually, enteric group is cultured from the ascitic fluid in majority of cases¹. The same organism is often recovered from blood culture. Most of the patients die, due to infection per se, others of its complications and some from other hazards of cirrhosis such as bleeding varices or the hepatorenal syndrome. Spontaneous bacterial peritonitis which first appeared to be a disorder of alcoholic cirrhosis, has also been reported in post-necrotic cirrhosis², chronic active hepatitis³, Nephrotic syndrome⁴, Cardiac cirrhosis⁵, malignant ascites and primary biliary cirrhosis⁶. The full blown syndrome may not be present and any one or all of its components may be missing. It may present as fever of unknown origin or as hypothermia. Sometimes it emerges as encephalopathy of uncertain cause. So unexplained fever, hypothermia, hypotension, encephalopathy, abdominal pain or simply unexplained clinical deterioration should be considered as the indications for diagnostic paracentesis in cirrhotics for the diagnosis of SBP⁷⁻¹². SBP is caused by enteric group of organisms by about 75% and the remainder by nonenteric including anaerobes. SBP being the problem in cirrhosis with ascites, all cirrhotics should be screened for SBP with at least ascitic fluid PMN cell count and culture of ascitic fluid. These patients are treated with antibiotics aggressively as they have poor prognosis and high mortality if not treated early. High degree of suspicion, routine diagnostic paracentesis, standardization of diagnostic criteria of ascitic fluid infection and use of non-nephrotoxic antibiotics is essential for early diagnosis and management. Early diagnosed and treated SBP episodes resolved satisfactorily and improved short-term prognosis. The long-term prognosis continues to be extremely poor. On the basis of these considerations, considerable efforts have been made in recent years to develop an alternative test for prediction of prognosis in patients with SBP. This represents an interesting and promising area of investigation, which could determine the further optimization of SBP management and further improvement in its prognosis. Ideally such a test should be performed at the bedside at the time of paracentesis and should have a high sensitivity and a low false-positive rate.

But studies evaluating the utility of ascitic fluid cell count in diagnosing SBP are few. Therefore, there is a need for more studies to validate the same. Hence, this study is being done to evaluate whether ascitic fluid PMN cell count can serve as useful prognostic markers for SBP. The study done to evaluate the importance of serial ascitic fluid PMN cell count showed that the serial ascitic fluid cell count can be used to monitor the treatment and in determining the duration of antimicrobial therapy in SBP^{13,14}.

II. Aims And Objectives

1. To study clinical features, pathogenic organisms, clinical course and outcome of spontaneous bacterial peritonitis.
2. To study the prognostic factors in spontaneous bacterial peritonitis.
3. The role of serial ascitic fluid polymorphonuclear cell count in predicting prognosis in patients of cirrhosis with ascites with spontaneous bacterial peritonitis.

III. Materials And Methods

Total of 50 patients of age group >20 years, diagnosed as SBP were studied thoroughly with regards to both history and clinical examination, under a special proforma. All patients who were confirmed of hepatic cirrhosis by ultra sound were screened for SBP were selected who were admitted in to ICU and Medical wards, Maharajah's Institute of Medical Sciences, Nellimarla, Vizianagaram from October 2014 to September 2016.

3.1 Inclusion criteria

- age group >20 years, diagnosed as SBP were studied thoroughly with regards to both history and clinical examination.

3.2 Exclusion criteria

- Cardiac cirrhosis
- Infiltrative liver disorders
- Chronic kidney disease
- Bleeding diathesis
- Biliary cirrhosis
- Malignant ascites
- Tuberculous bacterial peritonitis
- Meigs syndrome
- Secondary bacterial peritonitis
- Nephrotic syndrome

Ascitic fluid for analysis was aspirated as soon as the patients were admitted, before giving any antibiotics and before subjecting the patients for invasive procedures like liver biopsy, endoscopy or therapeutic aspiration. All patients underwent paracentesis within 24 hours of admission. About 40 ml of ascitic fluid was tapped in each patient with aseptic precautions. Blood contaminated or bloody ascitic fluids were discarded from the study.

1. 10ml of ascitic fluid was immediately inoculated into blood culture bottles at the bedside for proper transport to microbiological laboratory.
2. 10ml of ascitic fluid was sent to the laboratory in sterile test tubes for conventional culture.
3. 20ml of ascitic fluid was sent for biochemical and cytological examination.

Ascitic fluid of all patients was analyzed for the type of cells and cell count. Ascitic fluid was cultured to know the presence of pathogenic organisms. Due to lack of facilities, culture for anaerobes, fungi and viruses in the ascitic fluid could not be done in the present study. Patients were studied in detail in relation to clinical presentation, laboratory investigations, response to treatment, prognosis and outcome during the hospitalization. Special importance was given to serial ascitic fluid cell count and its relation to prognosis. Patients diagnosed of SBP were treated with I.V cefotaxime 2 grams 8 hourly.

3.3 Methodology of SBP Diagnose :

SBP diagnosed by following criteria

- An ascitic fluid PMN cell count greater than 250 cells/ mm³
Or
- An ascitic fluid cell count greater than 500 cells/ mm³
- With >50% PMN cells.
and
- An absence of a primary source of infection.

3.4 Investigations used:

Routine tests	Optional tests	Specific tests
WBC count & differential count	Total protein	Tuberculosis smear and Culture
Serum albumin	Glucose	Cytology
Cultures in blood-culture bottles	LDH	Triglyceride
SAAG	Gram staining	Bilirubin
	Amylase	

3.5 Calculations

Statistical Methods:

95% confidence Interval has been used to find the significance of study characteristics. ANNOVA test (multiple independent variables) has been used to find the significance of study parameters between Survived and Death taking P value of < 0.05 as significant. Receiving Operating Characteristics tool has been used to find the diagnostic performance of study parameters.

IV. Observation And Results

Total 50 patients of age group >20 years, diagnosed as SBP were studied thoroughly with regards to both history and clinical examination.

Table 1 Age Distribution of Patients

Age in years	Number	%
31-40	4	8.0
41-50	16	32.0
51-60	22	44.0
61-70	4	8.0
>70	4	8.0
Total	50	100.0
Mean±SD	53.68±9.06	




Table 2: Sex Distribution

Sex	Number	%
Male	36	72.0
Female	14	28.0
Total	50	100.0




Table 3: Etiology of Cirrhosis

Etiology	Number	Percentage
Alcoholic	37	74
HBsAg	8	16
Others	5	10




Table 4 Symptoms Distribution of Patients

Symptoms	Number	%	95% CI
Abdomen distension	50	100	100.00-100.0
Jaundice	32	64	49.19-77.08
Abdomen pain	28	56	41.25-70.01
Fever	28	56	41.25-70.01
Haemetemesis, Malena	18	36	22.92-50.81
Altered Sensorium	20	40	26.40-54.82
Oliguria	16	32	19.52-46.70




Table -5: Signs Distribution of Patients

Signs	Number	%
Fever	28	56
Icterus	42	84
Ascites	50	100
Abdominal tenderness	34	68
Petechiae, purpura, ecchymosis	16	32
Asterixis	24	48
Hypotension	12	24
Hepatomegaly	2	4
Splenomegaly	10	20




Table 6: Outcome SBP Patients

Outcome	Number	%	95% CI
Survived	28	56	41.25-70.01
Died	22	44	29.99-58.75




Table -7: Comparison of Investigations between the Patients of SBP- Died and Survived

Investigations	Outcome				P value
	Survived		Died		
	Mean	SD	Mean	SD	
Total count	8889.62	4496.50	10181.81	6671.59	0.41805
Total Bilirubin	4.91	2.55	6.62	3.35	0.04575
SGOT	109.71	44.71	125.00	46.98	0.83584
SGPT	66.07	34.86	94.18	25.23	0.83180
Sr.Albumin	2.24	0.34	2.08	0.21	0.46930
Sr.Creatinine	1.55	0.99	2.75	2.22	0.01423
AF Protein	1.02	0.20	0.96	0.39	0.50979




Table-8: Comparison of AF Cells Between the Patients Who Died and Survived

Investigations	Outcome				P value
	Survived		Died		
	Mean	SD	Mean	SD	
AF Cells(PMNs) 0 hours	567.85	295.40	990.90	816.15	0.01421
AF Cells(PMNs) 24 hrs	510.70	139.01	961.16	639.37	0.00017
AF Cells(PMNs) 48 hrs	262.85	127.27	631.81	367.92	0.00001
AF Cells(PMNs) 5 days	107.85	79.92	250.00	57.73	0.00187




Table – 9 Comparison of AF Cells Between the Patients Who Died and Survived

Investigations	Survived	Died
	% Change	% Change
AF Cells(PMNs) 0 hours	—	—
AF Cells(PMNs) 24 hrs	0.10%	0.30%
AF Cells(PMNs) 48 hrs	53.4%	35.9%
AF Cells(PMNs) 5 days	81.7%	74.1%




Table 10: Prediction of death Based on AF Cells (PMNs) at 0 Hour

AF cells at 0 hour	s	Sensitivity	95% CI	Specificity	95% CI	+LR	-LR
Cut-off							
>250	0.00	0.00	0.0 - 12.3	100.00	84.6 - 100.0	0.00	1.00
>250	7.14	7.14	0.9 - 23.5	100.00	84.6 - 100.0	0.00	0.93
>300	7.14	7.14	0.9 - 23.5	90.91	70.8 - 98.9	0.79	1.02
>400	42.86	42.86	24.5 - 62.8	90.91	70.8 - 98.9	4.71	0.63
>450	50.00	50.00	30.6 - 69.4	81.82	59.7 - 94.8	2.75	0.61
>500	57.14	57.14	37.2 - 75.5	81.82	59.7 - 94.8	3.14	0.52
>550	71.43	71.43	51.3 - 86.8	72.73	49.8 - 89.3	2.62	0.39
>600	71.43	71.43	51.3 - 86.8	63.64	40.7 - 82.8	1.96	0.45
>650	78.57	78.57	59.0 - 91.7	54.55	32.2 - 75.6	1.73	0.39
>700	78.57	78.57	59.0 - 91.7	45.45	24.4 - 67.8	1.44	0.47
>750	85.71	85.71	67.3 - 96.0	45.45	24.4 - 67.8	1.57	0.31
>950	85.71	85.71	67.3 - 96.0	18.18	5.2 - 40.3	1.05	0.79
>1300	100.00	100.00	87.7 - 100.0	18.18	5.2 - 40.3	1.22	0.00
>3200	100.00	100.00	87.7 - 100.0	0.00	0.0 - 15.4	1.00	0.00




Table-11: Prediction of Death Based on AF Cells (PMNs) at 24 Hours

AF Cells at 24 hour cut-off	Sensitivity	95% CI	Specificity	95%CI	+LR	-LR
>300	0.00	0.0-12.3	100.00	84.6-100.0	0.00	1.00
>500	57.14	37.2-75.7	100.00	84.6-100.0	0.00	0.43
>550	67.29	44.1-81.4	90.91	70.8*98.9	7.07	0.39
>600	64.29	44.1-81.4	63.64	40.7-82.8	1.77	0.56
>700	100.00	87.7-100.0	63.64	40.7-82.8	2.75	0.00
>2800	100.00	87.7-100.0	0.00	0.0-15.4	1.00	0.00




Table-12: Prediction of Death Based on AF Cells (PMNs) at 48 Hours

AF Cells at 48 hour cut-off	Sensitivity	95% CI	Specificity	95%CI	+LR	-LR
<100	0.00	0.0-12.3	100.00	84.6-100.0	0.00	1.00
>100	21.43	8.3-41.0	90.91	70.8-98.9	2.36	0.86
>200	42.86	24.5-62.8	90.91	70.8-98.9	4.71	0.63
>250	42.86	24.5-62.8	81.82	59.7-94.8	2.36	0.70
>270	50.00	30.6-69.4	81.82	59.7-94.8	2.75	0.61
>300	64.29	44.1-81.4	72.73	49.8-89.3	2.36	0.49
>350	78.57	59.0-91.7	72.73	49.8-89.3	2.88	0.29
>400	92.86	76.5-99.1	63.64	40.7-82.8	2.55	0.11
>450	92.86	76.5-99.1	54.55	32.2-75.6	2.04	0.13
>500	100.00	87.7-100	54.55	32.2-75.6	2.20	0.00
>1400	100.00	87.7-100	0.00	0.0-15.4	1.00	0.00




Table-13: Prediction of Death Based on AF Cells (PMNS)

AF Cells	Cutoff	Sensitivity	Specificity	+LR	-LR	AUROC
AF cells (PMN) 0 hrs	>600	71.43	63.64	1.96	0.45	0.727
AF cells (PMN) 24 hrs	>700	100.00	63.64	2.75	0.00	0.867
AF cells (PMN) 48 hrs	>450	92.86	54.55	2.04	0.13	0.808
AF Cells (PMN) 5 days	>200	85.71	68.18	2.69	0.21	0.927

Table-14: Ascitic Fluid Culture

AF Culture	Number	%
No Growth	24	48%
EC	12	24%
KP	10	20%

Proteus	2	4%
SA	2	4%
Total	50	100




Table-15: Blood Culture

Blood Culture	Number	%
No Growth	40	80.0
EC	2	4.0
KP	8	16.0
Proteus	-	-
SA	-	-




Fig-1: gross appearance




Fig-2: Microscopic features




Figure 3: gross appearance




Figure 4: microscopic features.



Figure 5: Clinical Features of Cirrhosis of Liver Patients




Figure -6: Development of Ascites in Cirrhosis

V. Discussion

This study was carried out on patients admitted to MIMS General Hospital, Nellimarla, Vizianagaram. Patients admitted for liver disorder and/ or its complications of hepatic cirrhosis were studied during the period from October 2014 to September 2016. USG machine was used to diagnose cirrhosis of liver and ascites giving special reference to caudate lobe, portal vein, and spleen. All patients who were confirmed of hepatic cirrhosis by ultra sound were screened for SBP.

Ascitic fluid for analysis was aspirated as soon as the patients were admitted, before giving any antibiotics and before subjecting the patients for invasive procedures like liver biopsy, endoscopy or therapeutic aspiration.

5.1 Age & Sex Distribution:

SBP was seen predominantly in male population i.e. 36 cases (72 %) and only 14 (28%) females. SBP was seen in predominantly older age group, with most patients in 6th decade. Mean age at the time of diagnosis was 54 years.

Mean age at the time of diagnosis in **Filik L, Unal S⁵⁹** was 49.9 while 39 in **N Rawat, MK Bhatnagar^{13,67}** series and 44 in **Mihās AA¹⁰** study. The mean is 54.1 years¹⁰ ranging from 28 to 74 years old and males are being 62% in **Rahul Pathak et al⁷⁰** 2015 study. The mean age in our series of cases was slightly higher than in other studies. While distribution of males and females was almost similar in all the studies.

5.2 clinical features of SBP

The common mode of presentation of SBP in our series was jaundice associated with fever, abdominal pain and abdominal tenderness.

In present series 64 % of cases had jaundice at presentation while it was 81% in **Jose Pinto Correira⁶** series and 54.5% in **Filik L, Unal S⁵⁹** series indicating decompensated cirrhosis. Jaundice was the commonest presenting complaint in all the series of patients including our patients.

In **S Bankar, A De, S Baveja et al⁷¹** 2014 study, jaundice (82.76%) is the commonest presentation followed by abdominal pain (82.56%) and fever (68.97%).

In **AK Bhardwaj et al⁷²** 2015 study, abdominal distention (100%) is the commonest presentation followed by abdominal pain (58%) and fever (62%).

Except for the **DN Amarapurkar³¹** study (28%) the incidence of hepatic encephalopathy was very high ranging from 46 % in **Mihās AA¹⁰** study, 48 % in present study, 50.7 % in **Filik L, Unal S⁵⁹** and as high as 71 % in **Jose Pinto Correira, Conn HO⁶** study indicating that patients were in advanced stage of cirrhosis.

The incidence of hepatic encephalopathy was very high in **Jose Pinto Correira, Conn HO⁶** study, probably due to unavailability of effective drugs. One of the reasons could also be unawareness of the complications like SBP at that time (1975), and lack of regular screening for SBP in all patients of ascites. Only 56 % of cases had fever and 56 % had abdominal pain at the time of presentation indicating that many patients of SBP may not have fever or abdominal pain and can just present with hepatic encephalopathy. So all patients presenting with encephalopathy without an obvious precipitating factor must be screened for SBP.

The incidence of abdominal pain and abdominal tenderness in our study was comparable to other studies

5.3 Mortality:

In **Jose P⁶** (1975) series the mortality was 96 % while in **Hoefs JC¹⁸** (1984) the mortality was 78 %. Both these study had high mortality due to non availability of higher antibiotics during that period. Now with advent of higher antibiotics like cephalosporins and quinolones the mortality has decreased. Also mortality may have been decreased due to increased awareness of SBP and more aggressive treatment.

The mortality in **DN Amrapurkar³¹**, **AK Bhardwaj et al⁷²** and **Filik L, Unal S⁵⁹** series was 43%, 32% and 37.4% which is similar to the mortality in present series (44%). Still the mortality of 44 % seen in our study is very high, as these patients present in advanced stage of cirrhosis.

5.4 Factors Predicting Mortality In SBP

Increased total leucocyte count, bilirubin above 5 mg/ dl and creatinine >1.5 mg / dl was significantly associated with increased mortality in our study.

Even studies by **Filik L, Unal S⁵⁹** and **N Rawat, MK Bhatnagar⁶⁷** showed association of increased total count, increased bilirubin levels and high creatinine levels with mortality.

In **Sort et al⁷⁸** and **Kamani et al⁷⁴** study, high creatinine and low serum albumin are associated with high mortality while in **AK Bhardwaj et al⁷²** study, increased total leucocyte count, high serum Bilirubin and creatinine, low serum albumin and low ascitic fluid albumin are associated with poor prognosis.

According to study by **Filik L, Unal S**⁵⁹ decreased serum albumin and ascitic fluid protein was related to mortality while the present study and study by **MK Bhatnagar, N Rawat**¹³ fails to find any such correlation. This could be because of the less number of patients studied.

In present study the serum albumin and ascitic fluid protein did not reach significance level though it showed a decreasing trend with increasing mortality.

5.5 Ascitic Fluid Analysis

Ascitic fluid protein plays an important role in developing SBP in these patients. Patients with ascitic fluid protein < 1 gm / dl are frequently predisposed to SBP. In **Runyon BA**²² series the patients with ascitic fluid protein < 1 gm/dl were more predisposed to development of SBP. In the series of **DN Amarapurkar**³¹ the mean ascitic fluid protein was 0.78 +/-0.24 gm/dl in patients of SBP. In **AK Bhardwaj et al**⁷² study, the mean ascitic fluid protein was 1.086+/-0.3 gm/dl indicating the role of low AF protein in developing SBP.

In the present series the mean ascitic fluid protein was 1.02 gm/dl indicating the role of low ascitic fluid in developing SBP. However the ascitic fluid protein was not significantly related to mortality.

5.6 Ascitic Fluid Cell Count

In the present series the ascitic fluid cell count at the time of diagnosis as well as that done at 48 hours was significantly related to outcome. A very high cell count at the time of diagnosis was associated with increased mortality. The ascitic fluid cell count done at 48 hours was also related significantly to outcome. The % fall in ascitic fluid cell count from 0 hours to 48 hours was also related significantly to mortality. Attainment of ascitic fluid cell count of <200 /dl after starting treatment, was associated with better outcome.

Thus a fall in ascitic fluid cell count from 0 hours to 48 hours after starting treatment indicates that a patient is responding to treatment and can be used as a guide to monitor treatment. A fall of ascitic fluid cell count < 200 can be used as a guide for duration of antibiotic therapy in treatment of SBP.

According to **AK Bhardwaj et al**⁷² study, the AF cell count at the time of diagnosis (>600 PMN cells) as well as that done at 48 hours (>450 PMN cells) was significantly related to outcome. The % fall in AF cell count from 0 hour to 48 hour was also related to mortality(28%). In **Krishnamurthy et al**⁷³ study also similar results were obtained.

According to study by **N Rawat, MK Bhatnagar**¹³ the ascitic fluid cell count at the time of diagnosis was not significantly related to mortality. This may have been due to less number of patients studied. While the ascitic fluid count done at 48 hours was significantly related to outcome. The attainment of ascitic fluid cell count of < 250 during the course of treatment was also associated with better outcome, which was consistent with the results of present study. ASCITIC FLUID CULTURE

In **Filik L, Unal S**⁵⁹ study the ascitic fluid culture positivity was 25.4 % with gram negative organisms being most frequently isolated organism (76.2 %).

In **DN Amarapurkar**³¹ series 47 patients showed ascitic fluid culture positive with 75 % showing growth of E. Coli and 1 (25%) patient showing growth of acenetobacter. In **Syed VA, Ansari JA et al**⁷⁵ study, culture positivity is 35% of patients showing E.coli 42.8% and K.pneumoniae 14.28% among culture positive cases.

According to Franca et al⁷⁶ culture positivity is 47% while in Runyon BA et al²² study, it was 60% and in David D et al study it was 63% positive for streptococci.

In another study by **A P Jain**⁶⁸ 88.8 % patients isolated organism with 44.44% growing coagulase positive staphylococci aureus. Rest grown Escherichia Coli, Pseudomonas and Klebsiella. In present series 48 % didn't show any growth, 24 % showed E.Coli and 20% showed growth of Klebsiella and 4 patient each, showing growth of proteus and staphylococcus aureus. In above patients blood culture was positive in 20 % of cases which was consistent with the results of other studies.

5.7 Limitations of the present study :

There are certain limitations to this study. This is a hospital based study, so the data may not represent the general population. A hospital population was examined and referrals were admitted selectively for severity of the symptoms and requiring immediate nursing and hospital care.

- Unintentional confounding may have potentially been introduced by the observational design of this study.
- The findings of this study potentially represent the unique microbiological ecology of our hospital and patient population
- Self prescribing is a common practice in Andhra Pradesh, so over the counter use of antibiotics, may not have been adequately addressed in this study
- Survival was confined to observation made while patients were admitted to hospital and was not assessed longitudinally for the outcome
- This study relied on patient for the symptoms and nursing staff, physicians for the documentation of signs

- Furthermore, statistical analysis and results are limited by the small study population
- This is a prevalence study so the cause effect relationship couldn't be obtained
- No controls were included in this study

5.8 Recommendations For Further Work:

Additional prospective studies with larger sample sizes are needed to radiate this study findings using ascitic fluid PMN cell count as prognostic indicator and in ascertaining appropriate diagnostic thresholds.

Strong efforts should focus on effective prophylactic measures with low or zero risk for the development of bacterial resistance.

The longterm follow up of the survived population would ensure the frequency of the recurrent cases of spontaneous bacterial peritonitis which will help in actual quantification of the problem and in formulating appropriate prevention measures.

VI. Conclusion

All patients of cirrhosis of liver with ascites should be screened for spontaneous bacterial peritonitis (SBP) as it presents with minimum signs and symptoms. A diagnostic paracentesis should always be performed routinely within 24 hours of admission and thereafter due to high prevalence of spontaneous bacterial peritonitis (SBP) in cirrhotic patients. Increased total count, elevated levels of bilirubin and elevated creatinine levels are associated with poor prognosis. Once spontaneous bacterial peritonitis (SBP) is diagnosed, serial ascitic fluid PMN cell count is helpful in predicting prognosis and should be used as tool for monitoring the treatment. Spontaneous bacterial peritonitis (SBP) carries a very high mortality and should be dealt with aggressively.

References

- [1]. Garcia-Tsao G., Spontaneous bacterial peritonitis: *Gastroenterol Clin North Am*, 1992; 21:257–275.
- [2]. Epstein M. Pneumococcal Peritonitis in patients with post necrotic hepatitis. *New Eng. J Med*, 1968; 278: 69.
- [3]. Wyle RJ. SBP a common complication of chronic active hepatitis. *European ASS. Study liver*, 1979:13.
- [4]. JS Sandhu, Parti, Chabra. SBP in Nephrotic syndrome. *JIMA*, 1991:316.
- [5]. Runyon BA. SBP associated with cardiac ascites. *Am J of GE*, 1984; 79:796.
- [6]. Jose Pinto Correia, Conn HO. SBP in cirrhosis endemic or epidemic? *Med Clin of North America*, 1975; 59:963.
- [7]. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. *Gastroenterology*, 2001; 120:726–748.
- [8]. Llovet JM, Planas R, Morillas R. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. *Am J Gastroenterol*, 1993; 88:388–392.
- [9]. Toledo C, Salmeron JM, Rimola A. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. *Hepatology* 1993; 17:251–257.
- [10]. Mihas AA, Toussaint J, Hsu HS, Dotherow P, Achord JL. Spontaneous bacterial peritonitis in cirrhosis: clinical and laboratory features, survival, and prognostic indicators. *HepatoGastroenterology* 1992; 39:520–522.
- [11]. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors, and prognosis. *Hepatology* 1994; 10:1495–1501.
- [12]. McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Surawicz CM, Owen, RL, editors. *Gastrointestinal and Hepatic*
- [13]. MK Bhatnagar, N Rawat; To Assess The Role of Serial Ascitic Fluid Cell Count in Treatment of Spontaneous Bacterial Peritonitis; *J Assoc Physicians India*; April 2006 ;53 ;350.
- [14]. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment, and prophylaxis of spontaneous bacterial peritonitis: a consensus document. *International Ascites Club. J Hepatol* 2000; 32:142–153.
- [15]. Vekataraman et al. Madurai: incidence of SBP in cirrhosis of liver with ascites. *Gold Apicon*, 1995:158; pp.37.
- [16]. Carroli and Platterborse Septicemirae portocavae cirrhosis du foie at septicemiae. *Scan Hop Paris*, 1958; 34:472.
- [17]. Conn HO. SBP variant syndromes. *South Med J*, 1987;80;11:1343-1346.
- [18]. Hoefs JG Runyon. SBP disease a month, 1985; 9:1-48.
- [19]. Mansour A. Parsi, Ashish Atreja, NIZAR N. ZEIN, *Cleveland Clinic Journal Of Medicine* ;vol 71;7 July 2004:569-76.
- [20]. Tsurumi H et al. SBP due to clostridium perfringens in a patient with liver cirrhosis. *Gastroenterol Japan*, 1992; 10; 27[5]:662-6G7.
- [21]. 21.Raymond T Chung, Daniel Podolsky; *Cirrhosis and Its Complications*; in *Harrisons Principles of Internal Medicine*; 16th ed.; Page 1858-69.
- [22]. Sheila Sherlock, James Dooley; *Hepatic Cirrhosis*; in *Diseases Of Liver And Biliary System*; Blackwell Science publishers; 11th ed.; page- 368-380.
- [23]. Anthony P.P. et al. *J.Clin.Pathol.* 31:395,1978
- [24]. Li CP, Lee FY, Hwang SJ, et al. "Spider angiomas in patients with liver cirrhosis: role of alcoholism and impaired liver function". *Scand. J. Gastroenterol.* 34 (5); 1999; 520-3.
- [25]. Horbin WP et al. Diagnosis of cirrhosis based on regional changes in hepatic morphology. *Radiology*, 1980; 135; 273.
- [26]. Grant, A; Neuberger J. "Guidelines on the use of liver biopsy in clinical practice". *Gut* 45 (Suppl 4): 1999; 1-11.
- [27]. Runyon BA. pathogenesis of SBR Sheila Sherlock text book of diseases of liver and biliary system, pp.119.
- [28]. Sharad C Shah: "complications of cirrhosis"; in *API Textbook of medicine: 7th edition*;2003;page- 614- 616.
- [29]. Jose´ Such and Bruce A. Runyon: *Spontaneous Bacterial Peritonitis*; *Clinical Infectious Diseases*; 1998;27 Oct.:669–76
- [30]. Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. *Hepatology* 1984;4:1209–11.
- [31]. Amarapurkar DN, Viswanathan N, Parikh SS, Kalro RH, Desai HG :Prevalence of spontaneous bacterial peritonitis. *J Assoc Physicians India*. 1992 Apr;40(4):236-8
- [32]. Guarner C, Soriano G. Spontaneous bacterial peritonitis. *Semin Liver Dis* 1997; 17:203–17.

- [33]. Runyon BA, Hoefs JC. Ascitic fluid analysis in differentiation of SBP from GIT perforation in to ascitic fluid; *Hepatology*, 1984; 4:447-50.
- [34]. Wisse E, DE Zanger et.al: The Liver Sieve: considerations conceiving the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse: *Hepatology*, 1978;5:683.
- [35]. Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. *Gastroenterology* 1993; 104:1722-1726.
- [36]. Such J, Guamer et al. Low C3 in cirrhotic ascites predisposes to SBP. *J. Hepatol*, 1988; 8[1]: 8-84.
- [37]. Smedsrod B et al. Scavenger functions of liver endothelial cells. *Bio chem J*. 1990; 266; 313.
- [38]. Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. *Hepatology* 1988; 8:6325.
- [39]. Runyon BA. Low protein concentration of ascitic fluid is predisposed to SBP. *GE*. 1986 vol 91; 6; 1343-1346.
- [40]. Runyon BA et al. Opsonic activity of human ascitic fluid, a potentially important protective mechanism against SBR. *Hep*, 1985 Jul-Aug; 5[4]:634-637.
- [41]. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. *Gastroenterology* 1993;104:1133
- [42]. Cohle LB et al. Bacteremia after endoscopic injection sclerosis. *GE endoscopy*, 1983; 29; 198.
- [43]. Rolando N, Gimson A, Philpott-Howard J, et al. Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. *J Hepatol* 1993; 18:290-294.
- [44]. Góbrera J et al. Aminoglycoside Nephrotoxicity in cirrhosis. *GE*, 1982; 82
- [45]. Felisart J, Rimola A, Arroyo V, et al. Randomized comparative study of efficacy and nephrotoxicity of ampicillin plus tobramycin versus cefotaxime in cirrhotics with severe infections. *Hepatology* 1985;5:457-62
- [46]. Mercader J, Gomez J, Ruiz J, et al. Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients. *Chemotherapy* 1989; 35(suppl 2):23-2
- [47]. Mesquita MA, Balbino ES, Albuquerque RS, et al. Ceftriaxone in the treatment of spontaneous bacterial peritonitis: ascitic fluid polymorphonuclear count response and short-term prognosis. *Hepatogastroenterology* 1997; 44:1276-1280.
- [48]. Gomez-Jimenez J, Ribera E, Gasser I, et al. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. *Antimicrob Agents Chemother* 1993; 37:1587-1592.
- [49]. Grange JD, Amiot X, Grange V, et al. Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twentyseven cases of cirrhotic patients. *Hepatology* 1990; 11:360-364.
- [50]. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. *Hepatology* 1990; 12:716-24.
- [51]. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. *Gastroenterology* 1991; 100:477.
- [52]. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. *Gastroenterology* 1992; 103:1267-72.
- [53]. Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis: an update. *Mayo Clin Proc* 1995; 70:365-370.
- [54]. Gribbin JC, Cor CJ. SBP in a healthy adult male. *Australia NZ J Surg*, 1990; 60[9]; 723-725.
- [55]. Brasf R, Kuckelt W et al. SBP without ascites anaesthesia. *Intensiv Med Notfallmed*, 1992; 27; 5:325-7.
- [56]. Tito L, Rionola A et al. Recurrence of SBP in cirrhosis, frequency and predictive factors. *Hepatology*, 1988; 8; 27.
- [57]. Penzelow G, Virdow R et al. Is the acidity or the ascitic fluid a reliable index in making the presumptive diagnosis of SBP? *Hep*, 1986; 6[2]:244-247.
- [58]. Attali P, Turner K et al. pH of ascitic fluid in diagnosis and prognostic value in cirrhosis and non-cirrhotic patients. *EG* 1986, 90[5]; 1255-1260.
- [59]. Filik L, Unal S: Clinical and laboratory features of spontaneous bacterial peritonitis. *East Afr Med J*; 2004 Sep; 81(9):474-9.
- [60]. Luce E, Nakagawa P et al. Important in the bacteriological diagnosis of peritonitis with use of blood culture bottle method. *Trans-Am Soc. Artificial Intra Organ*, 1982; 28:259-261.
- [61]. Runyon et al. Bed side inoculation of ascitic fluid to blood culture bottle for culture. *Arch Int Med*, 1987; 147:73-75.
- [62]. Bar Meir S et al. Analysis of ascitic fluid in cirrhosis. *Am J Dig Dis* 24; 136; 1979.
- [63]. Runyon BA, Hoefs. Ascitic fluid chemical analysis before and after developing SBP. *Hepatology*, 1985; 5:257-259.
- [64]. Weinstein MP, Lannini PB et al. SBP a review of 28 cases. Survival and factors influencing prognosis. *Am J Med*, 1978; 64; 592-598.
- [65]. Hoefs JC et al. SBP. *Hepatology*, 1982; 2:399-407.
- [66]. Ink O, Peletier G et al. Prognosis of SBP; *Gastroenterol Clin Biol*, 1989; 13:556-561
- [67]. N Rawat, MK Bhatnagar. Study of Prognostic Factors in Spontaneous Bacterial Peritonitis in Indian Population; *J Assoc Physicians India*; April 2006 ;53;350.
- [68]. Jain AP, Chandra LS, Gupta S, Gupta OP, Jajoo UN, Kalantri SP: Spontaneous bacterial peritonitis in liver cirrhosis with ascites; *J Assoc Physicians India*. ;1999 Jun;47(6):619-21
- [69]. Ghany M, Hoofnagle JH. Approach to the patient with liver disease. *Harrison's principles of internal medicine*. 2005;16(2):1808.
- [70]. Pathak R, Von Thun A, Singh KV, Khadga P, Sharma S. Serial Ascitic Fluid Analysis-Prognostic Marker for Adverse Outcome in Spontaneous Bacterial Peritonitis in Liver Cirrhosis?. *Journal of Advances in Internal Medicine*. 2015 Jan 1;4(7):6.
- [71]. Bankar S, De A, Baveja S. Study of ascitic fluid for diagnosis of spontaneous bacterial peritonitis (SBP) in adult patients with cirrhosis. *IJMAS*. 2014;3(1):1-9.
- [72]. A K Bhardwaj, Dwijen D, P Bhattacharjee, G Kar, B K Nath. Role of serial ascitic fluid analysis and other prognostic factors in spontaneous bacterial peritonitis. *IJSS*. 2015; 3(7):195-201.
- [73]. Krishnamurthy MS, Patil NC. Serial ascitic fluid analysis in treatment of SBP. *dept. of general medicine. BMC Bengaluru: RUGHS*; 2008.
- [74]. Kamani L, Mumtaz K, Ahmed US, Ali AW, Jafri W. Outcomes in culture positive and culture negative ascitic fluid infection in patients with viral cirrhosis: Cohort study. *BMC Gastroenterol* 2008;8:59.
- [75]. Syed VA, Ansari JA, Karki P, Regmi M, Khanal B. Spontaneous bacterial peritonitis (SBP) in cirrhotic ascites: a prospective study in a tertiary care hospital, Nepal.
- [76]. Callado França AV, Giordano HM, Sevá-Pereira T, Soares EC. Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. *Journal of gastroenterology*. 2002 Feb 20;37(2):119-22.
- [77]. Goel GA, Deshpande A, Lopez R, Hall GS, Van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. *Clinical Gastroenterology and Hepatology*. 2012 Apr 30;10(4):422-7.

- [78]. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *New England Journal of Medicine*. 1999 Aug 5;341(6):403-9.
- [79]. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. *Gut*. 2012 Feb 1;61(2):297-310.
- [80]. Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM, International Ascites Club. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. *Journal of hepatology*. 2000 Jan 31;32(1):142-53.
- [81]. Such J, Runyon BA. Spontaneous bacterial peritonitis. *Clinical infectious diseases*. 1998 Oct 1;669-74.
- [82]. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, DeVoss A, Satoskar RS, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. *Therapeutic advances in gastroenterology*. 2011 Sep 15;1756283X11417037.

Dr. Sushanth Vemuganti "A Study of Spontaneous Bacterial Peritonitis in Cirrhosis of Liver with Ascites with Special Reference to Serial Ascitic Fluid Cell Count as Prognostic Marker." IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol. 17, no. 1, 2018, pp. 17-32